Regeneron Gains After Eye-Drug Patent Victory Over Viatris

Regeneron Pharmaceuticals Inc. rose the most in almost two months after a court ruled that the drugmaker’s patent rights were infringed by a cheaper copy of its eye drug developed by Viatris Inc.